CD134 (OX40) Monoclonal Antibody (ACT35 (ACT-35)), eBioscience | Invitrogen 14-1347-37 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

CD134 (OX40) Monoclonal Antibody (ACT35 (ACT-35)), eBioscience

catalog :

14-1347-37

quantity :

2 mg

price :

US 1474.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

ACT35 (ACT-35)

reactivity :

human

application :

immunohistochemistry, flow cytometry, immunohistochemistry - paraffin section, immunohistochemistry - frozen section

citations: 7

Reference
Gu xe9 rin A, Moncada V xe9 lez M, Jackson K, Ogishi M, Rosain J, Mancini M, et al. Helper T cell immunity in humans with inherited CD4 deficiency. J Exp Med. 2024;221: pubmed publisher
Theodoraki M, Laban S, Jackson E, Lotfi R, Schuler P, Brunner C, et al. Changes in circulating exosome molecular profiles following surgery/(chemo)radiotherapy: early detection of response in head and neck cancer patients. Br J Cancer. 2021;125:1677-1686 pubmed publisher
Autio M, Leivonen S, Brück O, Mustjoki S, Mészáros Jørgensen J, Karjalainen Lindsberg M, et al. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. Haematologica. 2021;106:718-729 pubmed publisher
Reuben A, Spencer C, Prieto P, Gopalakrishnan V, Reddy S, Miller J, et al. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med. 2017;2: pubmed publisher
Nagase H, Takeoka T, Urakawa S, Morimoto Okazawa A, Kawashima A, Iwahori K, et al. ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori. Int J Cancer. 2017;140:686-695 pubmed publisher
Cooper Z, Reuben A, Spencer C, Prieto P, Austin Breneman J, Jiang H, et al. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology. 2016;5:e1136044 pubmed
Voo K, Foglietta M, Percivalle E, Chu F, Nattamai D, Harline M, et al. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer. 2014;135:2834-46 pubmed publisher

product information

Product Type :

Antibody

Product Name :

CD134 (OX40) Monoclonal Antibody (ACT35 (ACT-35)), eBioscience

Catalog # :

14-1347-37

Quantity :

2 mg

Price :

US 1474.00

Clonality :

Monoclonal

Purity :

Affinity chromatography

Host :

Mouse

Reactivity :

Human

Applications :

Flow Cytometry: 1 ug/test, Immunohistochemistry (Frozen): Assay-Dependent, Immunohistochemistry (Paraffin): Assay-Dependent

Species :

Human

Clone :

ACT35 (ACT-35)

Isotype :

IgG1, kappa

Storage :

4 C

Description :

OX40 is a protein receptor found on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system. When activated, OX40 promotes the proliferation and survival of T cells, leading to a stronger immune response against cancer cells and infectious agents. OX40 agonists, which are drugs that activate OX40, have shown promising results in preclinical and clinical studies as a potential immunotherapy for cancer. They can enhance the efficacy of other cancer treatments such as chemotherapy and checkpoint inhibitors, and may also have applications in autoimmune diseases and allergies.

Format :

Liquid

Applications w/Dilutions :

Flow Cytometry: 1 ug/test, Immunohistochemistry (Frozen): Assay-Dependent, Immunohistochemistry (Paraffin): Assay-Dependent

Aliases :

ACT35; ACT35 antigen; ATC35 antigen; CD134; CD134 antigen; IMD16; Ly-70; lymphoid activation antigene ACT35; MRC OX40; Ox40; OX40 antigen; OX40 cell surface antigen; OX40 homologue; OX40L receptor; TAX transcriptionally-activated glycoprotein 1 receptor; tax-transcriptionally activated glycoprotein 1; tax-transcriptionally activated glycoprotein 1 receptor; TNF receptor superfamily member 4; Tnfrsf4; tumor necrosis factor (ligand) superfamily member 4; tumor necrosis factor receptor superfamily member 4; tumor necrosis factor receptor superfamily, member 4; tumor necrosis factor superfamily, member 4; Txgp1; Txgp1l